Annaliesa Anderson | Vice President And Cso Bacterial Vaccines

Annaliesa Anderson, Vice President And Cso Bacterial Vaccines, Pfizer

Annaliesa Anderson PhD FAAM, has over 20 years of pharmaceutical research experience and is currently the Chief Scientific Officer for Bacterial Vaccines at Pfizer Inc. Her responsibilities include infectious disease vaccine R and D, surveillance and the assessment of the immunopathology of bacterial colonization and disease. Dr Andersons experience includes leadership roles for bacterial vaccine programs directed at the prevention of diseases due to Neisseria meningitidisStaphylococcus aureus and Clostridium difficile and Enterococcus sp. In this role, she has made substantial contributions to vaccine antigen discovery, preclinical proof of concept, clinical proof of concept and recently the licensure of the N. meningitidis serogroup B vaccine Trumenba®.


Day 2 - 10 Co-conferences @ 10:15

Experts in bacterial vaccines critiquing FireChats

Day 3 - 10 Co-conferences & Plenary @ 10:10

Are bacterial vaccines harder to develop?

  • What are the challenges in clinical efficacy trials?
  • Phase II Clostridium difficile vaccine
last published: 18/Jan/19 09:26 GMT

back to speakers

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington


To Sponsor Or Exhibit

Marc Rhys-Evans
+44 20 7827 5945




To Register

Tayyab Abbasi
+44 20 7092 1210




Press Relations

Karina Kusova
+44 20 7092 1071